MEG3 and neoplasm: RNA-based therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), those aimed at modulating MEG3 expression, often encounter issues such as rapid degradation by nucleases, poor cellular uptake, and limited bioavailability at the tumor site (176, 177).